{"entity":{"id":"nct07756281","kind":"trial","name":"First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is not yet recruiting.","summary":"The registry lists NCT07756281 as not yet recruiting, last updated 2026-08-10. Enrolment is 40 planned participants, an estimate. Interventions: SNV1521, daraxonrasib. Primary measures include Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities. No results are posted in the registry; this does not exclude separate publications.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07756281","url":"https://clinicaltrials.gov/study/NCT07756281"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["snv1521"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07756281","phase":"1","setting":"A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","sponsor":"Synnovation Therapeutics, Inc.","started":"2026-09","startedType":"estimated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07756281/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"snv1521","kind":"drug","name":"SNV1521","route":"/drugs/snv1521/"}]}}